Heart Test Laboratories has announced the start of a clinical study of its MyoVista device by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). The study will compare the results of the MyoVista test to an established testing method, cardiac Computed tomography angiography (CCTA). Matthew Budoff (Los Angeles Biomedical Research Institute at Harbor- UCLA Medical Center, Los Angeles, USA) is the principal investigator.
A press release reports that the study will compare MyoVista results to subclinical measures of atherosclerosis (CAC and CT angiography) in 200 patients at risk for coronary artery disease. Correlations between the MyoVista reading and the presence of calcified plaque, soft plaque, and CTA stenosis will be determined. The study is expected to last between six months to one year. The aim of the study is to confirm MyoVista as a reliable and sensitive marker of atherosclerosis. The press release notes that results from the study may provide a strong indication for the value of a MyoVista test to confirm coronary artery disease in clinical practice, and for the clinical application of MyoVista in management of coronary disease and atherosclerosis.
A novel electrocardiographic recording method, the MyoVista obtains and processes signal information in a way that permits high resolution of the electrical activity associated with the myocardium. The clinical set up of this technique is identical to traditional 12-lead ECG; however, the recording is focused on the early detection of myocardial abnormalities by non-linear analysis of electrophysiological phenomenon propagated by changes of cellular metabolism level in the cardiac muscle, and the direction, timing and velocity of ion flow. This novel assessment may be capable of detecting subclinical myocardial dysfunction in a variety of heart diseases, and may be especially of value in patients at risk for coronary artery disease.